Fig. 2: Most frequently applied second-line treatment regimens in multiple myeloma patients, initiation of second-line treatment 2003–2021.
From: Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
CYBORD cyclophosphamide-bortezomib-dexamethasone, D dexamethasone, Dara daratumumab, I ixazomib, K carfilzomib, MP melphalan-prednisone, P pomalidomide, R lenalidomide, T thalidomide, V bortezomib.
